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Abstract
Aims. Major depressive disorder (MDD) is characterised by a recurrent course and high
comorbidity rates. A lifespan perspective may therefore provide important information
regarding health outcomes. The aim of the present study is to examine mental disorders
that preceded 12-month MDD diagnosis and the impact of these disorders on depression
outcomes.
Methods. Data came from 29 cross-sectional community epidemiological surveys of adults in
27 countries (n = 80 190). The Composite International Diagnostic Interview (CIDI) was used
to assess 12-month MDD and lifetime DSM-IV disorders with onset prior to the respondent’s
age at interview. Disorders were grouped into depressive distress disorders, non-depressive
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distress disorders, fear disorders and externalising disorders. Depression outcomes included
12-month suicidality, days out of role and impairment in role functioning.
Results. Among respondents with 12-month MDD, 94.9% (S.E. = 0.4) had at least one prior
disorder (including previous MDD), and 64.6% (S.E. = 0.9) had at least one prior,
non-MDD disorder. Previous non-depressive distress, fear and externalising disorders, but
not depressive distress disorders, predicted higher impairment (OR = 1.4–1.6) and suicidality
(OR = 1.5–2.5), after adjustment for sociodemographic variables. Further adjustment for
MDD characteristics weakened, but did not eliminate, these associations. Associations were
largely driven by current comorbidities, but both remitted and current externalising disorders
predicted suicidality among respondents with 12-month MDD.
Conclusions. These results illustrate the importance of careful psychiatric history taking
regarding current anxiety disorders and lifetime externalising disorders in individuals with
MDD.
Introduction
Depressive disorders are ranked as the third leading cause of
‘years lived with disability’ worldwide (GBD 2017 Disease and
Injury Incidence and Prevalence Collaborators, 2018). This is
due in part to their high prevalence, with a lifetime prevalence
of 10.6% and a 12-month prevalence of 4.5% for major depressive
disorder (MDD) (Bromet et al., 2018). Additionally, MDD is
often characterised by a recurrent course (Hardeveld et al.,
2013), suggesting the importance of taking a lifespan perspective
when studying MDD (Hardeveld et al., 2010; Bockting et al.,
2015).
Comorbidity with other mental disorders is high in individuals
with MDD (e.g. Grant, 1995; Kessler et al., 2003; Alonso and
Lépine, 2007; Bromet et al., 2018). Since MDD has a rather late
median age of onset (AOO) (Kessler and Bromet, 2013), i.e.
around 38 years (Bromet et al., 2018), other mental disorders
with earlier AOOs, such as anxiety disorders (Goodwin, 2002;
Bittner et al., 2004; Beesdo et al., 2007; Mathew et al., 2011;
Kessler et al., 2012; Gundel et al., 2018) and behavioural disorders
(including oppositional defiant disorder (ODD), conduct disorder
(CD) and attention deficit hyperactivity disorder (ADHD))
(Kessler et al., 2012; Gundel et al., 2018) often precede first-onset
MDD. Assessing the clinical history of mental disorders in indi-
viduals with current MDD could provide valuable information
regarding management and treatment strategies, especially since
this history may be a prognostic marker of the further clinical
course of MDD (Wittchen et al., 2003). Mental disorder
comorbidity is predictive of depression outcomes, including
impairment (Andrews et al., 2001; Alonso et al., 2004; Kessler
et al., 2015) and suicidal thoughts and behaviours (Stein et al.,
2001; Bolton et al., 2010; Kessler et al., 2015). However, to our
knowledge, no study has comprehensively examined the associa-
tions between a wide range of mental disorders with an onset
before 12-month MDD diagnosis with multiple depression
outcomes.
The overall aim of the present study is to examine associations
between 12-month MDD, previous mental disorders and MDD
outcomes. First, we examine the strength of associations between
12-month MDD and preceding individual lifetime mental disor-
ders in the cross-national World Mental Health (WMH) surveys.
Second, we examine whether previous mental disorders, i.e. with
an onset prior to the respondent’s age at interview, are predictive




Data came from 29 cross-sectional surveys administered between
2001/2002 and 2015 in low/middle-income countries (Brazil,
Bulgaria, Colombia, Colombia (Medellin), China (Shenzhen),
Iraq, Lebanon, Mexico, Nigeria, Peru, Romania, South Africa
and Ukraine) and high-income countries (Argentina, Australia,
Belgium, France, Germany, Israel, Italy, Japan, the Netherlands,
New Zealand, Northern Ireland, Poland, Portugal, Spain, Spain
(Murcia), USA). A total of 145 990 respondents participated.
Adults were selected based on multistage clustered area probabil-
ity sampling designs designed to generate samples that were rep-
resentative of the household populations in each country.
Face-to-face interviews were conducted in respondent homes.
The details of sampling methods in the different countries are
described in detail elsewhere (Heeringa et al., 2008; Pennell
et al., 2008). The weighted average response rate across surveys
was 69.5%. Informed consent was obtained according to protocols
endorsed by local Institutional Review Boards. Further informa-
tion on the surveys is provided in online Supplementary Table 1.
MDD and other comorbid DSM-IV diagnoses
The WHO Composite International Diagnostic Interview (CIDI),
a fully structured interview administered by trained lay inter-
viewers, was used to assess DSM-IV mental disorders (Kessler
and Üstün, 2004). Interviews were administered in two parts to
diminish respondent burden. All respondents completed Part I,
assessing MDD and other core mental disorders. Part II, assessing
other disorders and disorder correlates, was administered to all
respondents with any lifetime Part I diagnosis and a probability
subsample of other respondents. Part II data were weighted to
adjust for the undersampling of Part I non-cases. Analyses for
this study were performed in the Part II sample (N = 80 190).
Since mental disorders are significantly correlated, which may
be indicative of shared underlying vulnerability factors, a model-
based approach of comorbidity of mental disorders was used
(Krueger and Markon, 2006). Grouping of DSM-IV disorders
was based on the underlying structure of disorders found previ-
ously in the WMH surveys (de Jonge et al., 2018). Given our
focus on MDD, we separated two groups of distress disorders:
depressive distress disorders (MDD and dysthymia (hierarchical))
and non-depressive distress disorders (generalised anxiety
2 Annelieke M. Roest et al.
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disorder (GAD) and post-traumatic stress disorder (PTSD)). Fear
disorders included agoraphobia (non-hierarchical), panic dis-
order, social anxiety disorder, specific phobia and (childhood or
adult) separation anxiety disorder. Externalising disorders
included intermittent explosive disorder, ADHD, CD, ODD, alco-
hol abuse, alcohol dependence, drug abuse and drug dependence.
The AOO of disorders was assessed using special recall probes
that have been shown to yield more plausible distributions of
AOO of disorders than conventional recall questions (Knäuper
et al., 1999). Lifetime comorbid disorders were taken into account
when they had an onset prior to the respondent’s age at interview,
regardless of whether or not they persisted into the past year.
Outcomes
Role impairment
Role impairment due to MDD was assessed with a modified
version of the Sheehan Disability Scale (SDS) (Leon et al.,
1997). This scale assesses impairment in different domains,
namely home management, ability to work, ability to form and
maintain close relationships, and social life, during the month
in the past year when MDD was most severe. Severe impairment
was defined as a score ⩾7 on a response scale of 0–10 for each
domain. Respondents were defined as having any severe impair-
ment if they scored ⩾7 in at least one domain. Additionally,
respondents were asked how many days in the past year they
were unable to work or carry out their normal activities because
of their depression, i.e. days out of role (Ormel et al., 2008).
Suicidal thoughts and behaviours
Respondents were asked whether they had ever seriously thought
about suicide, and if so, whether they had ever made a suicide
plan or attempted suicide. Respondents who reported these
experiences were asked whether these experiences had also
occurred in the past 12 months.
Statistical analysis
The actuarial method was used to calculate the median AOO
of MDD in respondents with 12-month MDD. We used logistic
regression to examine the association between 12-month MDD
and other mental disorders (controlling for country of origin). If
a specific disorder was not assessed in a particular country, that
country was not included in that analysis; however, if a country
assessed at least one of the disorders in a disorder group (e.g. fear
disorders), the country was included in the analysis of that disorder
group, and non-assessed disorders were assumed not to be present.
We also used logistic regression to examine the association
between previous mental disorder groups and depression out-
comes (role impairment and suicidality). Linear regression was
used for days out of role due to MDD in the past year, a continu-
ous outcome. The models included all disorder groups simultan-
eously. We tested three models: model 1 only controlled for
country of origin of the participant; model 2 additionally adjusted
for age and sex; and model 3 additionally adjusted for educational
status, marital status and employment status.
In post-hoc analyses, we added depression characteristics,
namely AOO of MDD, lifetime history of chronic MDD (duration
of longest episode >2 years) and severity of MDD in the worst
month of the past year (according to the Quick Inventory of
Depressive Symptomatology Self Report (QIDS-SR)) (Rush
et al., 2000), to model 3. Furthermore, in a previous study,
current, but not remitted anxiety disorders and dysthymia,
predicted MDD episode duration (ten Have et al., 2017). As our
main analyses include both remitted disorders and disorders
that had onset prior to the current age but persisted into the
past year, we distinguished remitted (i.e. no 12-month diagnosis)
from current disorders in additional post-hoc analyses.
Results
Sample characteristics
A full description of the sample’s characteristics stratified by
12-month MDD status is presented in online Supplementary
Table 2. The number of respondents who met the criteria for
12-month MDD was 6684. The (weighted) prevalence of
12-month MDD was 4.9% (standard error (S.E.) = 0.1). Of the
respondents with 12-month MDD, 66.8% were female. In this
group, the median age of MDD onset was 38 years (interquartile
range = 23–54) and 34.4% had a lifetime history of chronic MDD.
History of mental disorders
Among respondents with 12-month MDD, 92.0% (S.E. = 0.5) had
a prior history of MDD, and 94.9% (S.E. = 0.4) had a history of
any previous mental disorder (including previous MDD). After
excluding prior MDD episodes, this percentage dropped to
64.6% (S.E. = 0.9). Compared to respondents without 12-month
MDD, prevalence rates of all other mental disorders with an
onset prior to the respondent’s age at interview were statistically
significantly increased in respondents with 12-month MDD.
The ORs ranged from 1.7 (alcohol abuse) to 20.2 (dysthymia)
(see Table 1). ORs were largest for depressive distress disorders
(including previous MDD) (OR = 161.1; 95% CI 140.0–185.4;
p < 0.001), followed by non-depressive distress disorders (OR = 7.4;
95% CI 6.8–8.0; p < 0.001), fear disorders (OR = 4.8; 95% CI
4.5–5.2; p < 0.001) and externalising disorders (OR = 2.3; 95%
CI 2.1–2.5; p < 0.001).
Role impairment
Overall impairment rates in respondents with 12-month MDD were
58.6% (S.E. = 0.9) for any severe impairment, 35.2% (S.E. = 0.9) for
severe impairment in home management, 35.6% (S.E. = 0.9) for
severe impairment in ability to work, 33.7% (S.E. = 0.9) for severe
impairment in the ability to form and maintain close relationships,
and 40.2% (S.E. = 0.9) for severe impairment in social life.
Among respondents with 12-month MDD, those with a previ-
ous depressive distress disorder were less likely to be severely
impaired due to MDD in home management (OR = 0.6; 95% CI
0.4–0.8; p = 0.001), ability to work (OR = 0.6; 95% CI 0.4–0.8;
p < 0.001) and social life (OR = 0.6; 95% CI 0.4–0.8; p < 0.001)
compared to respondents without a previous mental disorder
(see model 1, Table 2). However, the association between history
of depressive distress disorders and ability to form and maintain
close relationships was not statistically significant (OR = 0.7; 95%
CI 0.5–1.0; p = 0.061). Respondents with a previous non-
depressive distress disorder (GAD or PTSD) or fear disorder
had significantly increased odds (ORs ranging from 1.3 to 1.7)
of impairment due to MDD in all roles, compared to respondents
without previous mental disorders. Respondents with a previous
externalising disorder also had an increased risk of impairment
in ability to work, social life and relationships (ORs = 1.2–1.3),
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but not of impairment in home management (OR = 1.0; 95% CI
0.8–1.2; p = 0.96). Adjustment for sex and age in model 2, and
additionally for education, marital status and employment in
model 3, did not change these findings (see Table 2).
Days out of role
The mean number of days out of role in the past year due to
MDD for participants with 12-month MDD was 36.4 (S.E. =
1.8). Compared to respondents with 12-month MDD without
previous mental disorders, those with previous depressive distress
disorders (B = 10.9; 95% CI 1.1–20.8; p = 0.030), non-depressive
distress disorders (B = 16.6; 95% CI 8.4–24.8; p < 0.001) or fear
disorders (B = 13.8; 95% CI 6.4–21.3; p < 0.001) had higher num-
bers of days out of role (online Supplementary Table 3). The
number of days out of role was not significantly higher for
respondents with previous externalising disorders (B = 5.1; 95%
CI −2.5 to 12.6; p = 0.19). After adjustment for sex and age, the
association for previous depressive distress disorders lost statis-
tical significance (B = 9.3; 95% CI −0.3 to 18.8; p = 0.057).
However, previous non-depressive distress disorders (B = 13.2;
95% CI 4.9–21.4; p = 0.002) and previous fear disorders (B = 14.1;
95% CI 6.8–21.4; p < 0.001) remained significant predictors of
days out of role even in the fully adjusted model.
Suicidal thoughts and behaviours
Of all respondents with 12-month MDD, 13.2% (S.E. = 0.5)
reported suicidal ideation in the past 12 months and 4.4%
(S.E. = 0.3) and 2.6% (S.E. = 0.2), respectively, reported suicide
plans and attempts over this period. Previous depressive distress
disorders were not significantly associated with 12-month suicidal
ideation, plan or attempt in any model (ORs = 0.9–1.3) (Table 3).
Previous non-depressive distress disorders were associated with
suicidal ideation, plan and attempts in respondents with
12-month MDD, but not all associations were statistically signifi-
cant in each model (ORs = 1.3–1.7) (see Table 3). Previous fear
disorders (ORs = 1.5–1.7) and previous externalising disorders
(ORs = 1.9–2.9) were consistently associated with suicidal idea-
tion, plan and attempt in all models.
Post-hoc analyses including MDD characteristics
When depression characteristics were added to the models, a
higher age of MDD onset and 12-month MDD severity were asso-
ciated with role impairment due to MDD (online Supplementary
Table 4). In this model, previous fear disorders were no longer
associated with role impairment in any of the roles, except social
life (OR = 1.2; 95% CI 1.0–1.5; p = 0.029). Associations between






% S.E. % S.E. OR 95% CI p
MDD 6.9 0.1 92.0 0.5 164.7 143.1–189.5 <0.001
Dysthymia 0.6 0.0 12.0 0.6 20.2 17.5–23.4 <0.001
Any depressive distress disorder 7.2 0.1 92.1 0.5 161.1 140.0–185.4 <0.001
Generalised anxiety disorder 3.4 0.1 22.8 0.7 7.7 7.0–8.5 <0.001
Post-traumatic stress disorder 3.1 0.1 15.7 0.6 5.4 4.8–6.0 <0.001
Any non-depressive distress disorder 5.6 0.1 32.0 0.8 7.4 6.8–8.0 <0.001
Agoraphobia 1.5 0.1 6.9 0.4 4.6 3.9–5.3 <0.001
Panic disorder 1.5 0.1 8.4 0.5 5.4 4.7–6.1 <0.001
Separation anxiety disorder 4.1 0.1 17.1 0.8 4.2 3.7–4.8 <0.001
Social anxiety disorder 4.0 0.1 17.6 0.7 4.6 4.2–5.1 <0.001
Specific phobia 7.4 0.1 23.7 0.8 3.4 3.1–3.8 <0.001
Any fear disorder 11.2 0.2 38.2 0.8 4.8 4.5–5.2 <0.001
Intermittent explosive disorder 2.9 0.1 10.9 0.6 3.2 2.8–3.8 <0.001
Attention deficit hyperactivity disorder 1.7 0.1 5.9 0.5 2.8 2.2–3.6 <0.001
Conduct disorder 1.9 0.1 5.0 0.5 2.0 1.5–2.5 <0.001
Oppositional defiant disorder 2.3 0.1 6.3 0.6 2.4 2.0–2.9 <0.001
Alcohol abuse 9.0 0.1 15.7 0.6 1.7 1.6–1.9 <0.001
Alcohol dependence 2.3 0.1 7.3 0.4 3.0 2.6–3.5 <0.001
Drug abuse 3.1 0.1 8.0 0.5 2.5 2.2–2.9 <0.001
Drug dependence 1.0 0.1 4.0 0.3 3.4 2.7–4.1 <0.001
Any externalising disorder 12.3 0.2 26.0 0.7 2.3 2.1–2.5 <0.001
MDD, major depressive disorder; S.E., standard error; OR, odds ratio; CI, confidence interval.
Analyses controlled for country.
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Table 2. Association between previous disorders and severe role impairment
Home Work Relationship Social Any
OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p
Model 1
No previous disorders (ref) – – – – –
Depressive distress disorders 0.6 0.4–0.8 0.001 0.6 0.4–0.8 <0.001 0.7 0.5–1.0 0.061 0.6 0.4–0.8 <0.001 0.7 0.5–0.9 0.004
Non-depressive distress disorders 1.7 1.4–2.0 <0.001 1.6 1.3–1.9 <0.001 1.7 1.4–2.0 <0.001 1.7 1.4–2.0 <0.001 1.6 1.4–1.9 <0.001
Fear disorders 1.3 1.1–1.6 <0.001 1.3 1.1–1.6 0.003 1.4 1.2–1.7 <0.001 1.5 1.2–1.7 <0.001 1.5 1.3–1.8 <0.001
Externalising disorders 1.0 0.8–1.2 0.96 1.2 1.0–1.5 0.025 1.3 1.1–1.5 0.004 1.3 1.1–1.5 0.006 1.3 1.1–1.6 0.001
Model 2
No previous disorders (ref) – – – – –
Depressive distress disorders 0.5 0.4–0.8 <0.001 0.5 0.4–0.8 <0.001 0.7 0.5–1.0 0.073 0.6 0.4–0.8 <0.001 0.6 0.5–0.9 0.004
Non-depressive distress disorders 1.6 1.3–1.9 <0.001 1.5 1.3–1.8 <0.001 1.7 1.4–2.0 <0.001 1.7 1.4–2.0 <0.001 1.6 1.3–1.9 <0.001
Fear disorders 1.3 1.1–1.6 0.002 1.3 1.1–1.6 0.002 1.4 1.2–1.7 <0.001 1.5 1.2–1.7 <0.001 1.5 1.3–1.8 <0.001
Externalising disorders 1.2 1.0–1.5 0.11 1.3 1.1–1.6 0.010 1.3 1.0–1.5 0.017 1.3 1.1–1.6 0.005 1.4 1.1–1.7 0.002
Model 3
No previous disorders (ref) – – – – –
Depressive distress disorders 0.5 0.4–0.7 <0.001 0.5 0.4–0.7 <0.001 0.7 0.5–1.0 0.051 0.6 0.4–0.8 <0.001 0.6 0.5–0.8 0.002
Non-depressive distress disorders 1.6 1.3–1.9 <0.001 1.5 1.2–1.8 <0.001 1.7 1.4–2.0 <0.001 1.6 1.4–1.9 <0.001 1.6 1.3–1.9 <0.001
Fear disorders 1.3 1.1–1.5 0.004 1.3 1.1–1.6 0.007 1.4 1.2–1.7 <0.001 1.5 1.2–1.7 <0.001 1.5 1.2–1.7 <0.001
Externalising disorders 1.1 0.9–1.4 0.21 1.3 1.0–1.6 0.016 1.2 1.0–1.5 0.032 1.3 1.1–1.6 0.010 1.4 1.1–1.7 0.003
MDD, major depressive disorder; OR, odds ratio; CI, confidence interval.
Association between severe role impairment and previous depressive distress, non-depressive distress, fear or externalising disorders, among respondents with 12-month MDD.
Depressive distress disorders: major depressive disorder and dysthymia; non-depressive distress disorders: generalised anxiety disorder and post-traumatic stress disorder; fear disorders: agoraphobia, panic disorder, separation anxiety disorder, social
anxiety disorder, specific phobia; externalising disorders: intermittent explosive disorder, attention deficit hyperactivity disorder, conduct disorder, oppositional defiant disorder, alcohol abuse, alcohol dependence, drug abuse and drug dependence.
Model 1: adjusted for country.
Model 2: adjusted for country, age, sex.






















ova de Lisboa, on 25 N
ov 2021 at 09:44:46, subject to the Cam
bridge Core term
s of use, available at
previous non-depressive distress disorders and previous externa-
lising disorders with role impairment remained statistically sig-
nificant (ORs = 1.1–1.4), with the exception of the association
between previous externalising disorders and work impairment
(OR = 1.1; 95% CI 0.9–1.4; p = 0.30).
Only previous fear disorders were associated with a higher
number of days out of role compared to respondents with
12-month MDD without previous mental disorders (B = 7.2;
95% CI 0.0–14.4; p = 0.049) after additional adjustment for
depression characteristics. Lifetime MDD chronicity and
12-month MDD severity were strongly related to days out of
role in this model (online Supplementary Table 5).
Additionally, previous non-depressive distress disorders were no
longer statistically significantly related to suicidal thoughts and
behaviours. However, previous fear and externalising disorders
(ORs = 1.4–2.1), as well as MDD severity, were associated with sui-
cidal ideation, plans and attempts (online Supplementary Table 6).
Post-hoc analyses on remitted disorders
After separating previous disorders into those still present in the
past 12 months and those that had remitted, 52.3% (S.E. = 0.9) of
participants with 12-month MDD had any current comorbidity,
while 12.3% (S.E. = 0.5) only had remitted comorbidity. Previous
mental disorders were only associated with role impairment
when they were also present in the past 12 months, with the
exception of remitted externalising disorders and social impair-
ment (OR = 1.3; 95% CI 1.0–1.6; p = 0.027) (Table 4). Similarly,
days out of role due to MDD and suicidal thoughts and beha-
viours were related to current, but not remitted, fear disorders
(online Supplementary Table 7 and Table 5). Current externalis-
ing disorders were associated with suicidal ideation (OR = 2.0;
95% CI 1.5–2.5; p < 0.001) and plans (OR = 2.6; 95% CI 1.8–3.8,
p < 0.001), but not with suicide attempts (OR = 1.6; 95% CI 0.9–
2.7; p = 0.10). Remitted externalising disorders, however, were
only significantly associated with suicide attempts (OR = 1.7;
95% CI 1.0–3.0; p = 0.0498) and not with suicidal ideation
(OR = 1.3; 95% CI 1.0–1.8; p = 0.06) or plans (OR = 1.5; 95%
CI 1.0–2.4; p = 0.07) (Table 5).
Discussion
To our knowledge, this is the first epidemiological study that com-
prehensively examined the history of mental disorders in indivi-
duals with current MDD and their impact on depression
outcomes. The results of this study show the importance of apply-
ing a lifespan perspective when studying MDD. We found that
95% of respondents with 12-month MDD had a previous mental
Table 3. Association between previous disorders and suicidality
Ideation Plan Attempt
OR 95% CI p OR 95% CI p OR 95% CI p
Model 1
No previous disorders (ref) – – –
Depressive distress disorders 0.9 0.6–1.3 0.43 1.2 0.7–2.2 0.52 1.0 0.5–1.9 0.92
Non-depressive distress disorders 1.4 1.2–1.7 <0.001 1.3 0.9–1.8 0.13 1.4 1.0–2.1 0.081
Fear disorders 1.7 1.4–2.0 <0.001 1.7 1.2–2.3 0.001 1.6 1.1–2.4 0.023
Externalising disorders 2.1 1.7–2.6 <0.001 2.9 2.2–3.8 <0.001 2.3 1.6–3.4 <0.001
Model 2
No previous disorders (ref) – – –
Depressive distress disorders 0.9 0.6–1.3 0.55 1.3 0.7–2.3 0.43 1.1 0.5–2.1 0.88
Non-depressive distress disorders 1.5 1.3–1.9 <0.001 1.4 1.0–2.0 0.032 1.7 1.1–2.5 0.010
Fear disorders 1.6 1.4–2.0 <0.001 1.7 1.2–2.3 0.002 1.5 1.0–2.3 0.043
Externalising disorders 1.9 1.6–2.3 <0.001 2.5 1.9–3.3 <0.001 2.0 1.3–3.0 0.002
Model 3
No previous disorders (ref) – – –
Depressive distress disorders 0.9 0.6–1.3 0.43 1.2 0.7–2.3 0.49 1.0 0.5–2.0 0.96
Non-depressive distress disorders 1.5 1.2–1.8 <0.001 1.3 1.0–1.8 0.090 1.6 1.1–2.4 0.021
Fear disorders 1.6 1.3–2.0 <0.001 1.6 1.2–2.1 0.003 1.6 1.1–2.5 0.018
Externalising disorders 1.9 1.5–2.3 <0.001 2.5 1.9–3.3 <0.001 2.0 1.3–3.0 <0.001
MDD, major depressive disorder; OR, odds ratio, CI, confidence interval.
Association between suicidality and previous depressive distress, non-depressive distress, fear or externalising disorders, among respondents with 12-month MDD.
Depressive distress disorders: major depressive disorder and dysthymia; non-depressive distress disorders: generalised anxiety disorder and post-traumatic stress disorder; fear disorders:
agoraphobia, panic disorder, separation anxiety disorder, social anxiety disorder, specific phobia; externalising disorders: intermittent explosive disorder, attention deficit hyperactivity
disorder, conduct disorder, oppositional defiant disorder, alcohol abuse, alcohol dependence, drug abuse and drug dependence.
Model 1: adjusted for country.
Model 2: adjusted for country, age, sex.
Model 3: adjusted for country, age, sex, education, marital status and employment status.
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disorder. Many had suffered from previous MDD episodes, con-
firming the recurrent and/or chronic nature of MDD and demon-
strating that first-onset cases are rare among people with a
12-month MDD episode. However, even after excluding previous
MDD, 65% of respondents reported previous mental disorders.
Compared to respondents without MDD, those with MDD had
higher lifetime prevalence rates of all other individual mental
disorders.
Previous disorders and depression outcomes
Importantly, previous mental disorders in respondents with
MDD were associated with impairment and suicidality. Previous
non-depressive distress disorders and fear disorders were most
strongly associated with impairment. These results are consistent
with other studies that reported high impairment rates in indivi-
duals with MDD and comorbid anxiety disorders (Wittchen et al.,
2003; Van Der Werff et al., 2010; Kessler et al., 2015) and
reinforce the clinical importance of anxiety symptoms in MDD
(Gaspersz et al., 2018). Further, previous non-depressive distress,
fear and externalising disorders were related to past-year suicidal
ideation, plans and attempts in respondents with 12-month
MDD. The strongest associations were found for previous exter-
nalising disorders, consistent with other epidemiological studies
that found associations between externalising psychopathology
and suicide attempts independent from internalising psychopath-
ology (Verona et al., 2004; Hills et al., 2005, 2009).
Surprisingly, previous depressive distress disorders were asso-
ciated with less frequent severe role impairment. However,
respondents with previous depressive distress disorders did have
a higher number of days out of role compared to respondents
with first-onset MDD, although this association did not remain
statistically significant after adjustment for covariates.
Individuals with recurrent or chronic MDD may be less likely
to report severe impairment in different domains as a result of
habituation or adaptation to depressive episodes (Kruijshaar
et al., 2003). For example, it is possible that recurrent or chronic
MDD has led to the individual having reduced activity in some
roles (e.g. being under-employed); an ability to function
adequately in a reduced role may or may not be interpreted as
impairment. However, individuals with recurrent or chronic
MDD may also have reduced insight regarding impairment. The
finding that people with previous depression do report a higher
number of days out of role, a more objective measure of impair-
ment, argues that reduced insight may play some role, yet this is a
post-hoc speculation. Previous research has found conflicting
results, with some other studies reporting that recurrence of
MDD was related to increased functional impairment and work
disability (Merikangas et al., 1994; Rytsälä et al., 2005), while
others also found lower reported impairment among those with
recurrent MDD (Kruijshaar et al., 2003; Van Der Werff et al.,
2010), although this latter finding lost statistical significance
after adjustment for depression characteristics, including symp-
tom severity (Van Der Werff et al., 2010). Interestingly, we
found that a history of depressive distress disorders remained a
protective factor for role impairment even after adjustment for
MDD characteristics, including severity.
Somewhat surprisingly, a history of depressive disorder was
not associated with 12-month suicidal ideation, plan or attempt.
This suggests that people with a longer history of depression are
not currently at higher risk of suicidal thoughts and behaviours
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that people with a longer history of depression do have a higher
lifetime risk of suicidality as risk increases over the years since
persons with (a history of) MDD remain vulnerable for suicidal
ideation over time (de Beurs et al., 2019).
Lifespan perspective to MDD and other mental disorders
Applying a lifespan perspective to MDD appears to be of import-
ance, since individuals with MDD are highly likely to have suf-
fered from previous MDD and other mental disorders and
these disorders predict current, and potentially also future,
depression outcomes. Other epidemiological studies have also
shown that comorbidity is associated with increased depressive
episode duration (ten Have et al., 2017), lower likelihood of
MDD remission (Kelly and Mezuk, 2017) and chronicity of
MDD (Satyanarayana et al., 2009; Murphy and Byrne, 2012; ten
Have et al., 2018). On the other hand, research findings have
not been consistent. For example, Hoertel et al. (2015) concluded
that patient accounts of previous mental disorders would prob-
ably not improve the prediction of future suicidality, because cur-
rent comorbid mental disorders explained the associations of
remitted mental disorders with suicide attempts. Our post-hoc
analyses also showed that most of the associations between
comorbid mental disorders and outcomes were explained by cur-
rent, rather than remitted, disorders, but our results contrast with
Hoertel et al.’s since we found that both current and remitted
externalising disorders were associated with 12-month suicidal
thoughts and behaviours. Another study also suggested residual
effects of (comorbid) psychopathology, finding that individuals
with previous internalising and externalising disorders still
reported higher functional impairment even 12 months after
remission of the disorder (Bijl and Ravelli, 2000).
Potential benefits of taking a lifespan perspective when exam-
ining mental disorders are probably not restricted to MDD.
Future studies could examine the role of previous disorders in
onset and associated disability of other mental disorders with a
relatively late median AOO such as panic disorder, or instead,
focus on early-onset disorders as causes or markers of future
psychopathology. For example, in another report of the WMH
surveys, specific phobia in childhood was predictive of other
internalising disorders as well as impairment throughout the
life course (de Vries et al., 2019).
Comparison with clinical studies
The results of the current study are in line with clinical studies.
Among outpatients with a primary diagnosis of current MDD,
91% had another lifetime mental disorder diagnosis (including
previous MDD) (Brown et al., 2001). Another study in outpati-
ents with MDD also showed high prevalence rates of lifetime
and current comorbidity (Zimmerman et al., 2002; Zimmerman
et al., 2008). However, these findings do raise the question of
whether these high comorbidity rates represent an artefact of cur-
rent diagnostic systems, for example, as a result of the increasing
number of diagnoses in the DSM (Maj, 2005a), while different
diagnoses may actually result from a single clinical entity (Maj,
2005b). Nevertheless, detecting the presence of comorbid psychi-
atric symptoms may be very relevant in clinical management
(Mai, 2005a). Indeed, the importance of taking comorbidity
into account was exemplified by Zimmerman et al. (2002); their
study showed that the majority of patients with primary MDD
and comorbidity wanted treatment to also focus on these
comorbid current disorders, partially remitted disorders or symp-
toms not meeting full diagnostic criteria (Zimmerman et al.,
2002). Unfortunately, underrecognition of comorbidity is likely
to be common in routine clinical care when unstructured clinical
evaluations are used and time is limited (Zimmerman et al.,
2008).
The importance of a lifetime approach to MDD in clinical care
has been advocated before, for example, by Bockting et al. who
argued that knowledge on risk factors of MDD recurrence, such
as number of previous MDD episodes, may guide treatment
choices (Bockting et al., 2015). The current study suggests the
importance of additionally taking other previous mental disorders
into account to further enhance personalised treatment, especially
since most associations between previous lifetime comorbid disor-
ders and current MDD outcomes remained statistically significant
even after adjustment for MDD characteristics.
Table 5. Association between previous disorders, divided into remitted or current comorbid disorders, and suicidality
Ideation Plan Attempt
OR 95% CI p OR 95% CI p OR 95% CI p
No previous disorder (ref) – – –
Depressive distress disorders 0.7 0.4–1.2 0.23 1.0 0.5–2.0 0.99 1.6 0.7–3.9 0.29
Non-depressive distress disorders (remitted) 0.7 0.5–1.1 0.10 0.5 0.2–0.9 0.029 0.9 0.4–2.0 0.86
Non-depressive distress disorders (current) 1.2 0.9–1.6 0.12 1.2 0.8–1.7 0.48 1.1 0.7–1.8 0.63
Fear disorders (remitted) 0.7 0.5–1.1 0.16 1.1 0.6–1.9 0.81 1.6 0.9–3.1 0.13
Fear disorders (current) 1.5 1.2–1.9 <0.001 1.5 1.0–2.1 0.029 1.7 1.1–2.7 0.024
Externalising disorders (remitted) 1.3 1.0–1.8 0.06 1.5 1.0–2.4 0.07 1.7 1.0–3.0 0.050
Externalising disorders (current) 2.0 1.5–2.5 <0.001 2.6 1.8–3.8 <0.001 1.6 0.9–2.7 0.10
MDD, major depressive disorder; OR, odds ratio; CI, confidence interval.
Association between suicidality and previous depressive distress, non-depressive distress, fear or externalising disorders, among respondents with 12-month MDD. Previous disorders are
divided into remitted and current disorders.
Depressive distress disorder: major depressive disorder and dysthymia; non-depressive distress disorder: generalised anxiety disorder and post-traumatic stress disorder; fear disorder:
agoraphobia, panic disorder, separation anxiety disorder, social anxiety disorder, specific phobia; externalising disorders: intermittent explosive disorder, attention deficit hyperactivity
disorder, conduct disorder, oppositional defiant disorder, alcohol abuse, alcohol dependence, drug abuse and drug dependence.
Analyses adjusted for country, age, sex, education, marital status, employment status and MDD characteristics (age on onset, chronicity and severity).
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Strengths and limitations
An important strength of the current study is the large,
cross-national sample, providing the opportunity to examine the
associations between MDD and histories of individual mental
disorders. Another strength is the comprehensive assessment of
multiple depression outcomes and post-hoc analyses that adjusted
for MDD characteristics and separated remitted from current
comorbid mental disorders. Yet this study also has several limita-
tions. First, disorders were retrospectively assessed, so recall bias
may be present, particularly with regard to retrospectively-
reported AOO (Johnson et al., 1997). Second, although we distin-
guished first-onset from non-first-onset MDD episodes, we did
not distinguish recurrent from persistent or chronic 12-month
episodes. However, post-hoc analyses were adjusted for lifetime
presence of chronic MDD. We also did not consider the duration
or severity of comorbid disorders, although it is likely that more
long-lasting and more severe comorbid disorders are more
strongly associated with MDD outcomes. Finally, we did not con-
sider the potential influence of prior treatment for either MDD or
comorbid disorders.
Conclusions
In this general population sample, almost all individuals with
12-month MDD had suffered from previous mental disorders.
Among these individuals, previous non-depressive distress and
fear disorders were particularly strongly associated with greater
role impairment, confirming the clinical importance of anxiety
in MDD. Previous externalising disorders were most strongly
associated with suicidal ideation, plans and attempts. The risks
of adverse depression outcomes associated with previous mental
disorders were reduced in strength, but did not disappear, after
adjustment for MDD characteristics. Risks were mostly conveyed
through current, rather than remitted, previous mental disorders,
except for the risk of impairment in social life and suicide
attempts associated with remitted externalising disorders. These
results illustrate the importance of careful psychiatric history tak-
ing regarding current anxiety disorders and lifetime externalising
disorders in individuals with MDD.
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